Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs

Robert J. F. Laheij, PhD
Miriam C. J. M. Sturkenboom, PhD
Robert-Jan Hassing, MSc
Jeanne Dieleman, PhD
Bruno H. C. Stricker, MD, PhD
Jan B. M. J. Jansen, MD, PhD

Context  Reduction of gastric acid secretion by acid-suppressive therapy allows pathogen colonization from the upper gastrointestinal tract. The bacteria and viruses in the contaminated stomach have been identified as species from the oral cavity.

Objective  To examine the association between the use of acid-suppressive drugs and occurrence of community-acquired pneumonia.

Design, Setting, and Participants  Incident acid-suppressive drug users with at least 1 year of valid database history were identified from the Integrated Primary Care Information database between January 1, 1995, and December 31, 2002. Incidence rates for pneumonia were calculated for unexposed and exposed individuals. To reduce confounding by indication, a case-control analysis was conducted nested in a cohort of incident users of acid-suppressive drugs. Cases were all individuals with incident pneumonia during or after stopping use of acid-suppressive drugs. Up to 10 controls were matched to each case for practice, year of birth, sex, and index date. Conditional logistic regression was used to compare the risk of community-acquired pneumonia between use of proton pump inhibitors (PPIs) and H₂-receptor antagonists.

Main Outcome Measure  Community-acquired pneumonia defined as certain (proven by radiography or sputum culture) or probable (clinical symptoms consistent with pneumonia).

Results  The study population comprised 364,683 individuals who developed 5,551 first occurrences of pneumonia during follow-up. The incidence rates of pneumonia in non–acid-suppressive drug users and acid-suppressive drug users were 0.6 and 2.45 per 100 person-years, respectively. The adjusted relative risk for pneumonia among persons currently using PPIs compared with those who stopped using PPIs was 1.89 (95% confidence interval, 1.36-2.62). Current users of H₂-receptor antagonists had a 1.63-fold increased risk of pneumonia (95% confidence interval, 1.07-2.48) compared with those who stopped use. For current PPI users, a significant positive dose-response relationship was observed. For H₂-receptor antagonist users, the variation in dose was restricted.

Conclusion  Current use of gastric acid–suppressive therapy was associated with an increased risk of community-acquired pneumonia.

For editorial comment see p 2012.
between use of acid-suppressive drugs and the risk of infections. We examined the association between the use of gastric acid-suppressive drugs and community-acquired pneumonia in a population-based cohort study.

**METHODS**

**Setting**

All data were retrieved from the Integrated Primary Care Information (IPCI) project, a general practice research database containing data from electronic patient records of a group of about 150 general practitioners in the Netherlands. Details of the database have been described. Briefly, the database contains the complete medical records of approximately 500,000 patients. The electronic records contain coded and anonymous data on patient demographics, reasons for visit (in free text), diagnoses (using the International Classification for Primary Care and free text) from general practitioners and specialists, referrals, laboratory findings, hospitalizations, and drug prescriptions, including their indications and dosage regimen. To maximize completeness of the data, general practitioners participating in the IPCI project are not allowed to maintain a system of paper-based records aside from the electronic medical records. The system complies with European Union guidelines on the use of medical data for medical research and has been proven valid for pharmacoepidemiologic research. The Scientific and Ethical Advisory Board of the IPCI project approved the study.

**Source Population and Exposure Cohorts**

The study started on January 1, 1995, and ended on December 31, 2002. The source population comprised all individuals with at least 1 year of valid database history, which means that the general practitioner supplied standard data for at least 1 year and the patient was registered for 1 year with the general practitioner. We required this pre-enrollment period to be able to characterize the patient and verify previous use of drugs and a history of pneumonia. All individuals were followed up from the moment they had 1 year of valid history until one of the following events: pneumonia, death, moving out of the practice area, or end of the study period, whichever came first. To retain patients without recent occurrence of pneumonia, we excluded all individuals who had a diagnosis of pneumonia in the pre-enrollment period.

From the source population, a study cohort of incident (no use in the year before enrollment) acid-suppressive drug users (those with at least 1 H2RA or PPI prescription) was identified. From this exposure cohort, we excluded all individuals who received acid-suppressive drugs in combination with antibiotics to eradicate *Heli* cobacter pylori infection. The duration of use of individual acid-suppressive drugs was calculated from the prescribed quantity and prescribed dosing regimen. Person-time of exposure was accumulated during follow-up time for calculation of incidence rates. Individuals who never used acid-suppressive drugs before or during the study period were considered unexposed; follow-up time was accumulated for calculation of incidence rates.

**Identification and Ascertainment of Pneumonia**

The first occurrence of pneumonia for each individual was identified through searches on diagnoses and free-text indicators of pneumonia. The medical records of all potential cases were reviewed manually to classify the pneumonia as certain (proven by thorax radiography or microbiological culture), probable (clinical symptoms consistent with pneumonia but no objective evidence), possible, or no pneumonia. Definitions of pneumonia vary widely. Some require only the presence of infiltrates on chest radiography, whereas others require only certain symptoms or signs. In our analysis, we included pneumonia proven by chest radiography or sputum culture (certain) or presence of respiratory symptoms (probable). Cases with certain or probable pneumonia caused by aspiration (n=5), obstruction (n=6), or nosocomial infection (n=13) were excluded. The date of first pneumonia was defined as the index date.

**Nested Case-Control Analysis**

To reduce confounding by indication, a nested case-control analysis was conducted within the cohort of persons who used acid suppressants during the study period. For each case of pneumonia, we randomly selected up to 10 controls from the cohort, matched on sex, year of birth, and index date to the case. Exposure to H2RAs and PPIs was classified separately by time since last use. Drug use was defined as current if the prescription length covered the index date and past if the end of the last prescription was before the index date. Past use was further categorized into recent past, past, and distant past if the end of the last prescription was less than 30 days ago, between 30 and 180 days ago, and more than 180 days ago, respectively.

Because all persons had used an acid-suppressive drug during the study period, we had no unexposed subjects. In analyses of the dose and duration effects of H2RAs and PPIs separately, we restricted the cases and controls to individuals who never used the other type of acid suppressant. Among current users of H2RAs or PPIs, we studied the active compound (cimetidine, famotidine, nizatidine, ranitidine, roxatidine, omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole), the defined daily dose for the H2RAs cimetidine, famotidine, nizatidine, ranitidine, and roxatidine, and for the PPIs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, the daily dosage (less than, equal to, and more than the defined daily dose), and the duration of use (<14 days, 14-28 days, 28-42 days, and >42 days). The defined daily dose for the PPIs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole is 20, 20, 30, 40, and 20 mg, respectively. The defined daily dose for the H2RAs cimetidine, famotidine, nizatidine, ranitidine, and roxatidine is 800, 40, 300, 300, and 150 mg, respectively.

**Covariates**

As covariates in the case-control analysis, we considered age, sex, and calen-
dar time (matching factors), the indication for therapy (cancer, peptic ulcer disease and gastroesophageal reflux disease with or without esophagitis, functional dyspepsia, and endoscopically uninvestigated), diabetes mellitus, heart failure, chronic obstructive lung disease (asthma and chronic obstructive pulmonary disease), lung cancer, stomach cancer, number of physician visits in the year before, use of antibiotics, and use of systemic immunosuppressive agents (glucocorticoids, cyclosporine). In patients empirically treated with gastric acid-suppressive drugs and endoscopically uninvestigated, the indication for therapy was unknown and may have varied from relevant organic disease (peptic ulcer disease and reflux esophagitis) to no organic abnormalities (ie, functional dyspepsia). The indication for the use of acid-suppressive drugs was obtained from the prescription records. For patients with more than 1 indication, the endoscopically verified diagnosis was used.

Data Analysis

Crude incidence rates of pneumonia in unexposed and exposed individuals were calculated by dividing the number of pneumonia cases by the corresponding person-years. Relative risks of pneumonia (plus 95% confidence intervals [CIs]) during current and recent use of H2RAs and PPIs were estimated with odds ratios (ORs) by using conditional logistic regression analysis adjusted for all covariates that were univariately associated with pneumonia (P<.10). Stratified analyses were conducted to explore the effect of season and age as effect modifiers. In addition, we stratified for presence of cancer.

A sensitivity analysis that excluded all probable cases was conducted to examine the effect of outcome misclassification. We then calculated the population attributable risk percentage. The attributable risk percentage is the percentage of exposed cases that can be attributed to exposure, which is calculated [(OR-1)/OR]. The attributable risk percentage (obtained from adjusted ORs) was subsequently multiplied with the incidence rate ratio in PPI- and H2RA-exposed individuals to obtain the expected incidence rate attributable to exposure. Because this rate is per 100 person-years and we express number needed to harm in number of persons, we calculated how many persons were necessary for 100 person-years of exposure by applying the mean duration of exposure. All analyses were conducted in SPSS/PC+, version 11 (SPSS Inc, Chicago, Ill). The level of significance for all statistical tests was 2-sided P<.05.

RESULTS

The source population comprised 364,683 persons who had on average 2.7 years of follow-up and 5551 first occurrences of pneumonia (Table 1). Eighteen percent of the 5551 pneumonia occurrences were confirmed by radiography or microbiological testing. During the study period, 19,459 individuals received a first prescription for acid-suppressive drugs, 10,177 H2RAs and 12,337 PPIs (some individuals used both). The mean duration of use for H2RAs was 2.8 months; for PPIs, 5.0 months. Most persons had not undergone endoscopy and were empirically treated for upper gastrointestinal tract symptoms.

In the exposed cohort, 185 persons developed a first pneumonia occurrence during use of acid-suppressive drugs and 292 after stopping their use. The incidence rate during use of PPIs was 2.5 per 100 person-years and during use of H2RAs, 2.3 per 100 person-years compared with 0.6 for nonusers. Patients using acid-suppressive drugs developed pneumonia 4.5 (95% CI, 3.8-5.1) times more often compared with those who never used acid-suppressive drugs. This association measure was not adjusted for potential confounders.

For the nested case-control analysis, 475 of the 477 patients who developed pneumonia during or after stopping acid-suppressive drug use could be matched to a total of 4,690 controls (31% of the pneumonia cases were confirmed by chest radiography or sputum test). Two cases could not be matched and were therefore excluded from the analysis. Cases more often had diabetes mellitus, heart failure, and pulmonary diseases; more frequently used immunosuppressants; and more frequently had used antibiotics than did controls in the previous year (Table 2). The indication for acid-suppressive therapy was not associated with the risk of pneumonia.

To investigate the association between use of acid-suppressive drugs overall and pneumonia, we first examined all acid-suppressive drugs together. Current use of acid-suppressive drugs was associated with a small increase in the risk of pneumonia (adjusted OR, 1.27; 95% CI, 1.06-1.54). To examine the effects of current use of H2RAs and PPI separately, we considered current combined use of both compounds in a separate group. Because the association between pneumonia and past or distant past use of acid-suppressive drugs was similar, we com-

<table>
<thead>
<tr>
<th>Table 1. Relative Risks for Community-Acquired Pneumonia by Exposure to Gastric Acid-Suppressive Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>No. of patients</td>
</tr>
<tr>
<td>Person-years</td>
</tr>
<tr>
<td>No. of cases of pneumonia</td>
</tr>
<tr>
<td>Unadjusted relative risk (95% CI)</td>
</tr>
</tbody>
</table>

Abbreviation: CI, confidence interval.

*Some patients used H2-receptor antagonists plus proton pump inhibitors.
Excluding pneumonia without a laboratory confirmation led to higher risk estimates for developing pneumonia: 2.2 (95% CI, 1.4-3.5) for PPIs and 1.7 (95% CI, 0.8-2.9) for H2RAs. There was no significant effect modification by age, season, or presence of cancer. The adjusted attributable risk percentage is 42% for PPIs and 37% for H2RAs. Therefore, 1.05 pneumonia cases per 100 person-years of PPI exposure can be attributed directly to the use of PPIs and 0.86 pneumonia cases during 100 person-years of H2RA exposure. Because the average duration of use was 0.23 years for H2RAs and 0.42 years for PPIs, this roughly translates to 1 case of pneumonia per 226 patients treated with PPIs and 1 case of pneumonia per 508 persons treated with H2RAs.

**COMMENT**

In this large cohort, current use of acid-suppressive drugs was associated with an increased risk of community-acquired pneumonia. The increase in risk was most pronounced for PPIs and showed a clear dose-response relationship, which supports a real biological effect. The results are in agreement with a previous small study that was conducted ad hoc in a clinical setting. This study showed that subjects using acid-suppressive drugs more often reported clinical manifestations of respiratory tract infections and complications compared with those who did not use acid-suppressive drugs.

**Table 2. Characteristics of Cases (With Pneumonia) and Controls**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cases (n = 475)</th>
<th>Controls (n = 4690)</th>
<th>Odds Ratio (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>1 (0.2)</td>
<td>3 (0.1)</td>
<td></td>
</tr>
<tr>
<td>20-40</td>
<td>52 (10.9)</td>
<td>544 (11.0)</td>
<td></td>
</tr>
<tr>
<td>41-60</td>
<td>146 (30.7)</td>
<td>1530 (30.8)</td>
<td></td>
</tr>
<tr>
<td>&gt;60</td>
<td>276 (58.1)</td>
<td>2883 (58.1)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>262 (55.2)</td>
<td>2770 (55.8)</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>62 (13.1)</td>
<td>466 (9.4)</td>
<td>1.47 (1.10-1.97)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>95 (20.0)</td>
<td>449 (9.1)</td>
<td>2.73 (2.06-3.62)</td>
</tr>
<tr>
<td>Chronic obstructive lung disease</td>
<td>195 (41.1)</td>
<td>945 (19.1)</td>
<td>3.03 (2.48-3.70)</td>
</tr>
<tr>
<td>Stomach cancer</td>
<td>3 (0.6)</td>
<td>19 (0.4)</td>
<td>1.71 (0.50-5.84)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>13 (2.7)</td>
<td>32 (0.6)</td>
<td>4.41 (2.29-8.50)</td>
</tr>
<tr>
<td>Current use of immunosuppressants</td>
<td>40 (8.4)</td>
<td>126 (2.5)</td>
<td>3.60 (2.47-5.23)</td>
</tr>
<tr>
<td>Antibiotics used in last year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>262 (55.2)</td>
<td>3554 (71.7)</td>
<td>1.00</td>
</tr>
<tr>
<td>1</td>
<td>111 (23.4)</td>
<td>861 (17.4)</td>
<td>1.74 (1.37-2.20)</td>
</tr>
<tr>
<td>&gt;=2</td>
<td>102 (21.5)</td>
<td>545 (11.0)</td>
<td>2.49 (1.95-3.19)</td>
</tr>
<tr>
<td>Indication for acid-suppressant use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td>1 (0.2)</td>
<td>9 (0.2)</td>
<td>1.19 (0.15-9.40)</td>
</tr>
<tr>
<td>Peptic ulcer disease</td>
<td>27 (5.7)</td>
<td>206 (4.2)</td>
<td>1.34 (0.88-2.05)</td>
</tr>
<tr>
<td>Gastroesophageal reflux disease</td>
<td>131 (27.6)</td>
<td>1481 (29.9)</td>
<td>0.90 (0.72-1.12)</td>
</tr>
<tr>
<td>Functional dyspepsia</td>
<td>56 (11.8)</td>
<td>661 (13.3)</td>
<td>0.85 (0.63-1.15)</td>
</tr>
<tr>
<td>Endoscopically uninvestigated</td>
<td>260 (54.7)</td>
<td>2603 (52.5)</td>
<td>1.00</td>
</tr>
</tbody>
</table>

Abbreviation: CI, confidence interval.  
*Matched on age, sex, and index date.

bined these 2 reference categories to have a more stable 2 reference category. The adjusted relative risk for pneumonia among persons currently using PPIs compared with those who stopped using PPIs was 1.89 (95% CI, 1.36-2.62). Current users of H2RAs had a 1.63-fold increased risk of pneumonia (95% CI, 1.07-2.48) compared with those who stopped.

Although there was variation between individual PPIs and H2RAs, numbers were small and the heterogeneity was not significant. A significant dose response was observed in current users of PPIs. Persons using more than 1 defined daily dose had a 2.3-fold increased risk of pneumonia compared with past use of acid suppressants (Table 3). The dose response was not observed for H2RAs, but the variation in dose of these drugs was limited. Among current users of PPIs or H2RAs, the risk seemed most pronounced among persons who started drug use within the last 30 days (Table 3).
troesophageal junction is a prevalent gastrointestinal disorder. Reflux of gastric contents into the lower esophagus even occurs in the majority of healthy individuals but usually does not result in clinical sequelae.

In this study, we were able to take advantage of the fact that in the Dutch health care system, all medical information is prospectively collected at general practices that cover the total population instead of subjects presenting in a clinical setting. As a consequence, the data are generalizable to the general population and are not prone to selection bias. Nevertheless, given its observational nature, this study should be interpreted in the light of its limitations. First, we cannot exclude that some misclassification of outcome occurred. Such misclassification might be false negative or false positive. False-negative misclassification by underestimation of pneumonia may have occurred because of the exclusion of the possible cases (ie, cases for which we had insufficient diagnostic information). False-positive misclassification was possible in the group of probable pneumonia; most of the mild pneumonia is dealt with in primary care and therefore is not confirmed by chest radiograph or microbiological testing. Although we classified as probable pneumonia only infections with all clinical symptoms of pneumonia, we may have included some patients with bronchitis. When we excluded all probable cases from the analysis, the detected associations became stronger. Diagnostic bias could have occurred if patients who were taking acid-suppressive drugs had better diagnostic evaluation than distant-past users; however, the percentage of certain cases confirmed by radiograph or sputum was similar for current users (32%) and distant-past users.

Second, misclassification of exposure may have occurred because we used outpatient prescription data and had no information about whether the prescription was actually dispensed and taken. It is likely, however, that such exposure misclassification was random and evenly distributed among cases and controls.

Third, one could suspect that pneumonia would be diagnosed especially when the patient was treated by the general practitioner, the so-called diagnostic classification bias. However, the results from our study showed that the risk for pneumonia was increased in current drug users (pneumonia was reported during prescription length) but also in patients for whom the last prescription was at least 30 days old (recent past). These patients were prob-

### Table 3. Odds Ratios for Community-Acquired Pneumonia in Patients Using Proton Pump Inhibitors or H2-Receptor Antagonists

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Cases</th>
<th>Controls</th>
<th>Unadjusted OR</th>
<th>Adjusted OR (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current PPIs</td>
<td>99 (20.8)</td>
<td>697 (14.1)</td>
<td>1.79</td>
<td>1.73 (1.33-2.25)</td>
</tr>
<tr>
<td>Current H2RAs</td>
<td>48 (10.1)</td>
<td>417 (8.4)</td>
<td>1.43</td>
<td>1.59 (1.14-2.23)</td>
</tr>
<tr>
<td>Current use of H2RAs and PPIs</td>
<td>36 (7.6)</td>
<td>247 (5.0)</td>
<td>1.89</td>
<td>1.76 (1.18-2.61)</td>
</tr>
<tr>
<td>Recent use of H2RAs or PPIs</td>
<td>28 (5.9)</td>
<td>243 (4.9)</td>
<td>1.47</td>
<td>1.44 (0.94-2.21)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI, confidence interval; DDD, defined daily dose; H2RAs, H2-receptor antagonists; NA, not applicable; OR, odds ratio; PPIs, proton pump inhibitors.

*Adjusted for matching factors, respiratory illness, long-term heart failure, diabetes mellitus, use of antibiotics, and use of immunosuppressants.

†Too few cases were available to calculate ORs.
ably no longer being treated by the general practitioner, making classification bias less likely.

Finally, proptopathic bias (ie, pneumonia symptoms) may have resulted in an acid-suppressive-drug prescription if patients received acid-suppressive drugs for symptoms related to pneumonia. However, on exclusion of all persons who began receiving acid-suppressive drugs within 1 week before the index date, the relative risk estimates did not change, and therefore proptopathic bias can be excluded.

We observed a large difference between the unadjusted incidence rate ratios and the adjusted ORs in the nested case-control study. The incidence rate ratio should be interpreted with caution because it compares users of acid-suppressive drugs (with more comorbidity) with nonusers, which may result in substantial confounding by indication.

In fact, we designed the nested case-control study to control for this confounding effect. As confounding factors, we included other respiratory illnesses, comorbidities, and drug use that are strongly associated with pneumonia. Inclusion of these confounders in the model did not change the estimates to a large extent, which implies that confounding was minimal.

Despite this outcome, we cannot exclude the presence of uncontrolled confounders, which is a limitation inherent in all unrandomized studies.

The effectiveness of acid-suppressive drugs in the treatment of upper gastrointestinal tract symptoms is excellent. Acid-suppressive drugs nevertheless seem to have some drawbacks. Persons using acid-suppressive drugs more often develop a community-acquired pneumonia compared with those who do not use acid-suppressive drugs, which is in general not a problem because the risk for developing pneumonia is low. The increased risk for pneumonia is a problem for patients who are at increased risk for infection, especially because community-acquired pneumonia is potentially dangerous. Groups of persons who are at increased risk for infection and for whom pneumonia is a major source of mortality have been identified. Pneumonia is more pronounced in persons with asthma or chronic obstructive lung disease, immunocompromised persons, children, and elderly persons. Elderly patients are likely to incur severe infection, which is partly due to a decreased immune response, including the natural reduction of gastric acid secretion after age 60 years. To avoid the calculated excess pneumonia, patients with asthma or chronic obstructive lung disease, immunocompromised persons, children, and elderly persons should be treated with acid-suppressive drugs only when necessary and with the lowest possible dose.

In conclusion, our results suggest that acid-suppressive drugs such as H-RAs and PPIs are associated with an increased risk of community-acquired pneumonia, probably because of reduction of gastric acid secretion, facilitating oral infections.

Author Contributions: Dr Laheij had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Laheij, Strukkenboom.

Acquisition of data: Laheij, Strukkenboom, Hassing.

Analysis and interpretation of data: Laheij, Strukkenboom, Dielemann, Stricker, Jansen.

Drafting of the manuscript: Laheij, Strukkenboom, Stricker, Jansen.

Critical revision of the manuscript for important intellectual content: Hassing, Dielemann.

Statistical analysis: Laheij, Strukkenboom, Stricker.

Administrative, technical, or material support: Hassing.

Study supervision: Jansen.

REFERENCES